SOCIJALNA KOGNICIJA U BOLESNIKA SA PARKINSONOVOM BOLEŠĆU I POREMEĆAJIMA KONTROLE IMPULSA
Sažetak
Uvod: Parkinsonova bolest (PB) je sporo progresivna degenerativna bolest koju karakterišu tremor, rigiditet, bradikinezija i posturalna nestabilnost. Patogeneza PB se odlikuje neurodegeneracijom dopaminergičkih neurona. Prevalencija iznosi 1% u populaciji preko 60 godina. Hronična upotreba antiparkinsone terapije dovodi do psihomotornih i autonomnih komplikacija. Poremećaji kontrole impulsa (PKI) se opisuju kao nemogućnost osobe da se odupre impulsu ili težnji ka određenom ponašanju, a koje donosi štetu toj osobi ili njenoj okolini i narušava svakodnevno funkcionisanje. Socijalna kognicija je sposobnost zaključivanja o drugoj osobi putem percepcije njenih emocija i trenutnog mentalnog stanja.
Cilj rada: U našem radu smo ispitivali socijalnu kognciju kod pacijenata sa Parkinsonovom bolešću između onih koji imaju PKI i onih pacijenata koji nemaju PKI.
Materijali i metode: U studiji je učestvovalo 24 pacijenata sa dijagnozom Parkinsonove bolesti, od kojih su 13 pacijenata imali PKI dok 11 pacijenata nije imalo PKI. Učesnici su dijagnostikovani i testirani na Klinici za neurologiju u Univerzitetskom Kliničkom Centru Srbije. Korišćeni testovi su test čitanja emocija u očima (Reading the Mind in the Eyes Test ,RMET) i Test prepoznavanja socijalno neprihvatljivih priča (Faux-Pas Recognition Test) prilagođeni na srpski jezik.
Rezultati: Testiranjem razlike između grupe bolesnika sa i bez PKI nije nađena statistički značajna razlika u pogledu starosti bolesnika, pola, dužine trajanja bolesti, prisustva motornih komplikacija i uzimanja terapije levodopa, dopaminskih agonista ili amantadina. Nađena je statistički značajna razlika u postignućima na testovima socijalne kognicije između bolesnika sa PB i zdravim kontrolama.
Zaključak: Nađena je statistički značajna razlika u postignućima na testovima socijalne kognicije između bolesnika sa PB i zdravim kontrolama. U našem radu nije pokazana statistički značajna razlika u postignućima na testovima emocionalnog prepoznavanja i testovima teorije uma između grupe bolesnika koji su imali PKI i one bez PKI.
Reference
1. Kouli A, Torsney KM, Kuan WL, Stoker TB, Greenland JC. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications; 2018.
2. Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci. 2017; 18(3):551.
3. Zafar S, Yaddanapudi SS. Parkinson Disease. In: StatPearls. Treasure Island (FL): StatPearls; 2021.
4. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26(1): 1-58.
5. Zhang JF, Wang XX, Feng Y, Fekete R, Jankovic J, Wu YC. Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. Front Psychiatry. 2021; 12:635494.
6. Christidi. F, Migliaccio. R, Santamaría-García. H, Santangelo. G, Trojsi, F. Social Cognition Dysfunctions in Neurodegenerative Diseases: Neuroanatomical Correlates and Clinical Implications. Behavioural neurology. 2018; 2018(3): 1-18.
7. Patin A, Hurlemann R. Social cognition. In: W. Rosenthal, editor. Handbook of Experimental Pharmacology. London:Springer;2015. p. 271-309.
8. Tamaš O, Kostić M, Kačar A, Stefanova E, Salak-Đokić B, Stanisavljević D, et al. Social Cognition in Patients With Cerebellar Neurodegenerative Disorders. Front Syst Neurosci. 2021; 15:664223.
9. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51(6):745–52.
10. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003; 18(7):738-750.
11. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver- Dunckley ED, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. 2009; 24(10):1461–1467.
12. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001; 42(2):241-251.
13. Baron-Cohen S, O'Riordan M, Stone V, Jones R, Plaisted K. Recognition of faux pas by normally developing children and children with Asperger syndrome or high-functioning autism. J Autism Dev Disord. 1999; 29(5):407-418.
14. Đorđević J, Živanović M, Pavlović A, Mihajlović G, Stašević-Karličić I, Pavlović D. Psychometric evaluation and validation of the Serbian version of 'Reading the Mind in the Eyes' test. Psihologija. 2017; 50(4):483-502.
15. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol. 2008;15(1):14-20.
16. Botha H, Carr J. Attention and visual dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18(6):742-747.
17. Gray HM, Tickle-Degnen L. A meta-analysis of performance on emotion recognition tasks in Parkinson's disease. Neuropsychology. 2010; 24(2):176-191.
18. Bora E, Walterfang M, Velakoulis D. Theory of mind in Parkinson's disease: A meta-analysis. Behav Brain Res. 2015; 292:515-520.
19. Foley JA, Lancaster C, Poznyak E, Borejko O, Niven E, Foltynie T, et al. Impairment in Theory of Mind in Parkinson's Disease Is Explained by Deficits in Inhibition. Parkinsons Dis. 2019; 2019:5480913.
20. Bora E, Walterfang M, Velakoulis D. Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: a meta-analysis. J Neurol Neurosurg Psychiatry. 2015; 86(7):714-719.
21. Gatto EM, Aldinio V. Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review. Front Neurol. 2019; 10:351.
22. Lopez AM, Weintraub D, Claassen DO. Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy. Semin Neurol. 2017; 37(2):186-192.